Celladon said it expected to cut jobs after the company's experimental gene therapy to treat heart failure failed a key trial.» Read More
For biotech watchers, it's deja vu all over again. Through Wednesday, the Nasdaq Biotechnology Index dropped 6.9 percent since the close March 20.
Investors are bailing on biotech stocks at such a rapid pace that it is shocking even some of the most-seasoned traders.
Eric Schmidt, Cowen & Company analyst, provides perspective on the biotech space after the Nasdaq biotech index posted its worst daily drop since December.
Major pharmaceuticals companies have formed a partnership with Genomics England in the first step towards using genetic data from NHS patients.
"Fast Money" traders discussed how to play Wednesday's selloff in biotech, transportation and technology names.
Janet Yellen may be right … about eight months late though.
CNBC screened the large cap S&P 500 index to see where the hottest parts of the dividend stock market have been.
Susquehanna's Stacey Gilbert thinks biotech could be due for a pullback. She lays out an options strategy to protect your biotech holdings.
CNBC's Meg Tirrell reports the latest on Stifel downgrading Biogen and Pfizer making a positive move. CNBC's Brian Sullivan and Melissa Lee weigh in on the biotech sector.
Jean-Jacques Bienaime, BioMarin Pharmaceuticals CEO, discusses his company's bull run and new drugs to treat rare diseases, including Duchenne muscular dystrophy.
Biogen has seen its value quadruple to more than $100 billion on the back of its successful multiple sclerosis drugs. Now it has new ambitions.
Big-name biotech stocks have been on a tear, but some "Fast Money" traders warned the run may not continue.
Why the biotech space still has room to run, with John Stoltzfus, Oppeneimer, and the "Closing Bell" panel.
Biotechs and small caps are the top performers on Wall Street, with the health-care subsector up about 8 percent for the week.
As the biotech sector and names such as Biogen continue to surge, finding value is becoming increasingly difficult, an expert says.
David Seaburg, Cowen & Co., and Ari Wald, Oppenheimer, join "Power Lunch" to discuss the biotech rally.
Yaron Werber, Citi Investment Research, discusses recent Biogen activity and his investment outlook on the stock. "This stock has upside," says Werber.
CNBC's Dominic Chu reports which biotech stocks are fueling the run higher in the iShares Nasdaq Biotech ETF, the IBB.
Biologists called for a ban of a new genome-editing technique in a way that the DNA can be inherited, The New York Times reports.
CNBC's Meg Tirrell reports the biotech company got better than expected results regarding its Alzheimer's drug.
Get the best of CNBC in your inbox